NOTICE OF MEETING MARCH 11, 2019 The National Emerging Infectious Diseases Laboratories...
Original article from Boston 25 NewsAugust 2, 2018
A lab in Boston was approved to study one of the world’s deadliest viruses.
On Thursday, Boston University’s National Emerging Infectious Diseases Laboratories (NEIDL) announced in a press release that they have started experimenting with the Ebola virus.
NEIDL microbiologist Elke Mühlberger said the lab’s first project will examine how the Ebola virus damages cells in the liver and why it triggers such a powerful inflammatory response.
Mühlberger said the answers to those questions could speed the development of how to treat the Ebola virus disease. In a 2014-2016 outbreak, the virus led to more than 11,000 deaths in West Africa. And a few months ago in May, an Ebola outbreak in the Democratic Republic of Congo killed 29 people.
The researchers at NEIDL are also experimenting with the Marbug virus. Like Ebola, Marburg is deadly and causes convulsions and bleeding of mucous membranes, skin and organs, according to the Centers for Disease Control and Prevention.
Mühlberger said their plans include at least three projects involving both the Ebola and Marburg viruses. But the first step of their work will be growing the rare Level-4 pathogens to produce enough materials for their experiments.
Original article from NBC Boston by Caroline ConnollyAugust 3, 2018
A high security lab in Boston just received a sample of a deadly virus that has killed thousands — Ebola.
The pathogen arrived at Boston University’s National Emerging Infectious Diseases this week, along with the related Marburg virus. They are the first of their kind to arrive at the facility, which is allowed for labs classified as Level 4. The designation has only been given to 10 labs in the country.
“If you can’t stop them when the outbreak happens, then you’re out in the position to try to play catch-up,” the lab’s director, Ron Corley, said of the research.
Utilizing a variety of scientists who work in Boston’s academic community, Corley said they expect to make significant strides in better understanding the Ebola virus and its characteristics.
“This is exactly the place to have a facility like this,” said Corley. “That allows us to get people who would not normally think about trying to solve these problems to get interested.”
Original article from: WGBH News posted on January 4, 2018. by Cristina Quinn
After years of neighborhood battles, Boston University has won approval to conduct biosafety level 4 research. In layman’s terms, that means they can now study the world’s deadliest pathogens at the university’s National Emerging Infectious Disease Lab on the medical school’s South End campus.
Rows of blue and white protective lab suits hang in the changing room of a simulation of Boston University’s biosafety level 4 lab, also known as BSL-4. The real lab is in an inner sanctum of the building with 12-inch thick walls and 14-inch heavily fortified concrete flooring designed to withstand an earthquake.
Coiled air hoses hang from the ceiling. Microbiologist Elke Muhlberger grabs one to demonstrate how it works. Pointing to a socket on the waist of the suit, she takes the end of the hose and snaps it in. Air immediately starts hissing into the suit.
Original article from: STAT posted on October 20, 2017. by Hyacinth Empinado
Research on dangerous pathogens like Ebola takes place inside highly secure biosafety level-4 (BSL-4) labs. Elke Mühlberger, a researcher at the National Emerging Diseases Laboratory at Boston University, takes you as close to Ebola as you’ll ever get and talks about why she thinks of the deadly virus as her pet.
The BU Annual Fund Leadership Giving Society presents a conversation with Dr. Ronald Corley, professor and chair of the microbiology at the BU School of Medicine and director of the National Emerging Infectious Diseases Laboratories (NEIDL).
Dr Dennis Carroll is Director of the Emerging Threats Program at the U.S. Agency for International Development. We spoke to him at EIDA2Z about the current approach to tackling emerging diseases – and how we need to change it.
Eva Harris, PhD, University of California, Berkley, is interviewed by Vincent Racaniello, PhD, Columbia University, New York, about the status of Zika virus in Nicaragua. Harris has developed a multidisciplinary approach to study the molecular virology, pathogenesis, immunology, epidemiology, clinical aspects, and control of the mosquito-borne diseases dengue, Zika, and chikungunya. Her work investigates viral and host factors that modulate disease severity and immune correlates of protection and pathogenesis, using in vitro approaches, animal models, and research involving human populations.
Hosts: Vincent Racaniello, Alan Dove, and Paul Duprex
Guests: Ralph Baric, Felix Drexler, Marion Koopmans, and Stacey Schultz-Cherry
From the EIDA2Z conference at Boston University, Vincent, Alan and Paul meet up with Ralph Baric, Felix Drexler, Marion Koopmans, Stacey Schultz-Cherry to talk about discovering, understanding, protecting, and collaborating on emerging infectious diseases.
Become a patron of TWiV! https://www.patreon.com/microbetv
Links for this episode EIDA2Z meeting MERS-CoV infection of Alpaca (EID) Origins of HAV in small mammals (PNAS) WHO recommendations on influenza vaccine composition Collaborative Cross mice
Send your virology questions and comments to email@example.com
Sir Roy Anderson is a Professor at Imperial College London and the Director of the Centre for Neglected Tropical Disease Research.
He told us about the need for an institute combining governments, scientists and industry for rapid action in the case of a global pandemic.
Professor William Bishai is co-Director of the Johns Hopkins Center for Tuberculosis Research.
He spoke to us at EIDA2Z about the importance of global action on tuberculosis – which, despite being the leading infectious cause of death in the world, rarely makes the headlines.